在过度治疗的老年人中,在一般实践中实施降血糖药物干预的可行性
Charlotte Andriessen1,2, Marieke T Blom1,2, Beryl A C E van Hoek1,2
1Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Family practice
|September 5, 2025
概括
对2型糖尿病 (T2D) 的老年患者实施缓解处方计划 (DPP) 显示出可行性. 这项涉及教育和支持的计划需要与常规的全科医院护理保持一致,以便成功整合和减少药物使用.
科学领域:
- 老年医学
- 内分泌学
- 一般实践研究
背景情况:
- 患有2型糖尿病的老年患者经常服用过多的降血糖药物.
- 过度治疗可能会导致不良反应和增加医疗费用.
研究的目的:
- 评估在一般实践中实施解药方案的可行性.
- 为一个更大规模的随机对照试验收集见解.
主要方法:
- 一种混合方法方法,使用定量数据 (患者资格,减产率) 和定性数据 (提供者采访,培训分析).
- 扩展标准化过程理论指导了实施障碍和促进因素的分析.
- 这项研究涉及10名全科医生和医疗保健提供者.
主要成果:
- 在65名符合条件的T2D患者中,有55人接受了降血糖药物治疗,22人重新开始服用药物治疗.
- 实践护士认为培训和实践访问是有助的,但常规护理之外的任务不一致地执行.
- 调整了DPP以减少医疗人员的工作量,并与现有的实践程序相结合.
结论:
- 在一般实践中成功实施DPP需要全面的教育,实践支持访问和与日常护理流程的整合.
- 对于持续的采用,与现有工作流程调整描述计划至关重要.
- 根据可行性调查结果,需要通过随机对照试验进行进一步的研究.
相关概念视频
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Psychosis: Goals of Pharmacotherapy
208
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
208
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255


